Serologic Tumor Markers, Clinical Biology, and Therapy of Prostatic Carcinoma

Urologic Clinics of North America

Volumn 26, Issue 2, 1999, Pages 281-290

  Kim, J ^a   Logothetis, C J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROCORTISONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; SURAMIN; VINBLASTINE; VINCA ALKALOID;

ANDROGEN METABOLISM; CANCER CYTODIAGNOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; META ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; SERODIAGNOSIS; TREATMENT OUTCOME;

EID: 0032936780     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70068-9     Document Type: Article

References (92)

1. P.A. Abrahamsson S. Falkner K. Falt The course of neuroendocrine differentiation in prostatic carcinomas: An immunohistochemical study testing chromagranin A as an “endocrine marker.” Pathol Res Pract 185 1989 373
2. R.J. Amato J. Ellerhorst C. Bui Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate Urol Oncol 1 1995 168
3. A.G. Aprikian C. Cordon-Cardo W.R. Fair Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma Cancer 71 1993 3952
4. Y. Arai T. Yoshiki O. Yoshida Prognostic significance of prostate specific antigen in endocrine treatment of prostatic cancer J Urol 144 1990 1415
5. E.M.J.J. Berns A.L.G. Schuurmans J. Bolt Antiproliferative effects of suramin on androgen responsive tumour cells Eur J Cancer 26 1990 470
6. W.R. Berry J. Laszlo E. Cox Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate Cancer 44 1979 763
7. N.K. Bissada A.T. Kaczmarek Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol J Urol 153 1995 1944
8. N. Bruchovsky P.S. Rennie A.J. Coldman Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 2275
9. D.P. Byar The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32 1973 1126
10. N.B. Calcaterra L.R. Vicario O.A. Roveri Inhibition by suramin of mitochondrial ATP synthesis Biochem Pharmacol 37 1988 2521
11. C. Capella U.R. Buffa B. Frigerio The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate: Histochemical and ultrastructural identification of the endocrine cells Histopathology 5 1981 175
12. R.J. Coffey E.B. Leof G.D. Shipley Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells J Cell Physiol 132 1987 143
13. E.H. Cooper T.G. Armitage M.R.G. Robinson Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer Cancer 66 1990 1025
14. M.R. Cooper R. Lieberman R.V. LaRocca Adaptive control with feedback strategies for suramin dosing Clin Pharmacol Ther 52 1992 11
15. E.D. Crawford M.A. Eisenberger D.G. McLeod A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419
16. N.A. Dawson M.R. Cooper W.D. Figg Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables Cancer 76 1995 453
17. N.A. Dawson D.G. McLeod Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome J Urol 153 1995 1946
18. De Voogt H.J. S. Suciu R. Sylvester Multivariate analysis of prognostic factors in patients with advanced prognostic cancer: Results from 2 European Organization for Research on Treatment of Cancer trials J Urol 141 1989 883
19. Di Sant'Agnese P.A. Neuroendocrine differentiation in carcinoma of the prostate Cancer 70 1992 254
20. Di Sant'Agnese P.A. de Mesy Jensen K.L. Neuroendocrine differentiation in prostatic carcinoma Hum Pathol 18 1987 849
21. Dupont A. Gomez J.-L. L. Cusan Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy J Urol 150 1993 908
22. M.A. Eisenberger E.D. Crawford M. Wolf Prognostic factors in stage D2 prostate cancer: Important implications for future trials: Results of a cooperative intergroup study (INT.0036) Semin Oncol 21 1994 613
23. M.A. Eisenberger V.J. Sinibaldi L.M. Reyno Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer J Clin Oncol 13 1995 2174
24. W.D. Figg O. Sartor M.R. Cooper Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer Am J Med 98 1995 412
25. S.D. Fossa D.P. Dearnaley M. Law Prognostic factors in hormone-resistant progressing cancer of the prostate Ann Oncol 3 1992 361
26. S.D. Fossa E. Paus M. Lindegaard Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment Br J Urol 69 1992 175
27. S.D. Graham Critical assessment of prostate cancer staging Cancer 70 1992 269
28. C.E. Hensey D. Boscoboinik A. Azzi Suramin, an anticancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A FEBS Lett 258 1989 156
29. N. Hoosein M. Abdul R. McCabe Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer Urologic Oncology 1 1995 246 251
30. N.M. Hoosein Neuropeptides in the progression of prostate cancer Cancer Bull 45 1993 436
31. M. Hosang Suramin binds to platelet-derived growth factor and inhibits its biological activity J Cell Biochem 29 1985 265
32. S.D. Huan R.G. Gerridzen J.C. Yau Antiandrogen withdrawal syndrome with nilutamide Urology 49 1997 632
33. G.R. Hudes R. Greenberg R.L. Krigel Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer J Clin Oncol 10 1992 1754
34. G.R. Hudes F. Nathan C. Khater Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer J Clin Oncol 15 1997 3156
35. G.R. Hudes C. Obasaju A. Chapman Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer Semin Oncol 22 1995 6
36. C. Huggins C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
37. J.T. Isaacs D.S. Coffey Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 1981 5070
38. B.A. Kazzaz Argentaffin and argyrophil cells in the prostate J Path 112 1974 189
39. W.K. Kelly H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome J Urol 149 1993 607
40. W.K. Kelly T. Curley C. Leibertz Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer J Clin Oncol 13 1995 2208
41. W.K. Kelly H.I. Scher M. Mazumdar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607
42. J.M. Kozlowski W.J. Ellis J.T. Grayhack Advanced prostatic carcinoma: Early versus late endocrine therapy Urol Clin North Am 18 1991 15
43. S.H. Landis T. Murray S. Bolden Cancer Statistics, 1998 CA Cancer J Clin 48 1998 6
44. R.V. LaRocca R. Danesi M.R. Cooper Effect of suramin on human prostate cancer cells in vitro J Urol 145 1991 393
45. R.V. LaRocca J. Meer R.W. Gilliatt Suramin-induced polyneuropathy Neurology 40 1990 954
46. M.E. Leo D.L. Bilhartz E.J. Bergstralh Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 145 1991 802
47. A. Levin P.S. Gill J. Cohen Suramin antiviral therapy in AIDS: Clinical, immunological, and virological results Ann Intern Med 105 1986 32
48. C.W. Mahoney A. Azzi Huang K.-P. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C J Biol Chem 265 1990 5424
49. H. Matzkin P. Eber B. Todd Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer Cancer 70 1992 2302
50. R. Melzack The McGill pain questionnaire: Major properties and scoring methods Pain 1 1975 277
51. M.V. Merrick C.L. Ding G.D. Chisholm Prognostic significance of alkaline and acid phosphatase and scintigraphy in carcinoma of the prostate Br J Urol 57 1985 715
52. H. Mitsuya M. Popovic R. Yarchoan Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III Science 226 1984 172
53. M.J. Moore D. Osoba K. Murphy Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer J Clin Oncol 12 1994 689
54. P.F.A. Mulders G.A. Dijkman Fernandez del Moral P. Analysis of prognostic factors in disseminated prostatic cancer Cancer 65 1990 2758
55. C. Myers M. Cooper C. Stein Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 1992 881
56. M. Nakajima A. DeChavigny C.E. Johnson Suramin: A potent inhibitor of melanoma heparanase and invasion J Biol Chem 266 1991 9661
57. E.P.N. O'Donoghue A.R. Constable T. Sherwood Bone scanning and plasma phosphatases in carcinoma of the prostate Br J Urol 50 1978 172
58. D.F. Paulson W.R. Berry E.B. Cox Treatment of metastatic endocrine unresponsive carcinoma of the prostate gland with multiagent chemotherapy: Indicators of response to therapy J Natl Cancer Inst 63 1979 615
59. D.P. Petrylak H.L. Scher A. Li Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy Cancer 70 1992 2870
60. K.J. Pienta D.C. Smith Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer Semin Oncol 24 1997 15 72
61. K.J. Pienta B. Redman M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005
62. M. Pollak M. Richard Suramin blockade of insulin like growth factor 1—Stimulated proliferation of human osteosarcoma cell J Natl Cancer Inst 82 1990 1349
63. L.M. Reyno M.J. Egorin M.A. Eisenberger Development and validation of a pharmacokinetically based fixed dosing scheme for suramin J Clin Oncol 13 1995 2187
64. B.J. Roth B.Y. Yeap G. Wilding Taxol in advanced, hormone-refractory carcinoma of the prostate Cancer 72 1993 2457
65. E.K. Rowinsky L.A. Cazenave R.C. Donehower Taxol: A novel investigational antimicrotubule agent J Natl Cancer Inst 82 1990 1247
66. D.L. Schaffer H.P. Pendergrass Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate Radiology 121 1976 431
67. H.I. Scher W.K. Kelly Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer J Clin Oncol 11 1993 1566
68. H.I. Scher G. Steineck W.K. Kelly Hormone-refractory (D3) prostate cancer: Refining the concept Urology 46 1995 142
69. H. Schipper J. Clinch A. McMurray Measuring the quality of life of cancer patients: The functional living index-cancer: Development and validation J Clin Oncol 2 1984 472
70. J.D. Schmidt W.W. Scott R. Gibbons Chemotherapy programs of the National Prostatic Cancer Project (NPCP) Cancer 45 1980 1937
71. A.D. Seidman H.I. Scher D. Petrylak Estramustine and vinblastine: Use of prostate specific antigen as clinical trial end point for hormone refractory prostatic cancer J Urol 147 1992 931
72. Selby P.J. Chapman J.-A.W. J. Etazadi-Amoli The development of a method for assessing the quality of life of cancer patients Br J Cancer 50 1984 13
73. N.H. Slack A. Mittelman M.F. Brady The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer Cancer 46 1980 2393
74. E.J. Small P.R. Carroll Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome Urology 43 1994 408
75. E.J. Small N.J. Vogelzang Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm J Clin Oncol 15 1997 382
76. E.J. Small M.E. Marshall L. Reyno Superiority of suramin + hydrocortisone (S + H) over placebo + hydrocortisone (P + H): Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer (HRPC) [Abstract 1187] Proceedings of American Society of Clinical Oncology 17 1998 308
77. D.C. Smith R.L. Dunn M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835
78. P.H. Smith A. Bono Calais da Silva F. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer Cancer 66 1990 1009
79. L.A. Speicher L. Barone K.D. Tew Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines Cancer Res 52 1992 4433
80. G. Steineck W.K. Kelly M. Mazumdar Acid phosphatase: Defining a role in androgen-independent prostate cancer Urology 47 1996 719
81. I. Tannock M. Gospodarowicz W. Meakin Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590
82. I.F. Tannock D. Osoba M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756
83. I. Tannon E. Janot Essai de traitement de la maladie du sommeil au cameroun, par le Bayer 205. Action sur les parasites. Action sur le rein de foie Ann Parasit Hum Comp 2 1924 327
84. B. Tetu J.Y. Ro A.G. Ayala Small cell carcinoma of the prostate part I: A clinicopathologic study of 20 cases Cancer 59 1987 1803
85. G.N. Thalmann R.A. Sikes S.M. Chang Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer J Natl Cancer Inst 88 1996 794
86. The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer N Engl J Med 311 1984 1281
87. M. Toji S. Lelievre Y. Benchokroun Suramin induces apoptosis in DC-3F Chinese hamster fibrosarcoma cells Proceedings of the American Association for Cancer Research 34 1993 293
88. Tu S.-M. L.C. Pagliaro M.E. Banks Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer Clin Cancer Res 4 1998 1193
89. D.A. Twillie M.A. Eisenberger M.A. Carducci Interleukin-6: A candidate mediator of human prostate cancer morbidity Urology 45 1995 542 549
90. J. Veldscholte C. Ris-Stalpers C.C.J.M. Kuiper A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Comm 173 1990 534
91. D. Warr S. McKinney I. Tannock Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response J Clin Oncol 2 1984 1040
92. C.G. Wood L. Finn C.J. Logothetis Prostate specific antigen (PSA) to tumor burden ratio: A prognostic variable in androgen-independent prostate cancer (AIPC) [Abstract 1155] J Urol 157 1997 297